Automation of
            <scp>PET</scp>
            Radiopharmaceutical Quality Control

Elizarov, Arkadij M.

doi:10.1002/9781119500575.ch14

Cited by 5 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Traditional QC methods are costly as they require a range of tests across multiple analytical instruments including a radio-HPLC, gas chromatograph, dose calibrator, and others. 117,146 A well-developed QC platform fully integrated with a microfluidic synthesis module is critical to the goal of decentralized radiotracer production. This would allow a technician to simply load the raw radioactive material and relevant precursors and solvents, start the machine, and receive a fully qualified human-ready dose of tracer without any further interaction.…”

Section: Safety and Regulatory Considerationsmentioning

confidence: 99%

“…Elizarov has written an extensive chapter detailing the history and progress made of QC regulations and commercial equipment. 146 In 2017, Trace-Ability, Inc. released the Tracer-QC which revolutionized QC of radiotracers by generating all necessary validation data from measurements produced by a plate reader. Because it includes an integrated HPLC, this methodology eliminates the need for several different bulky machines.…”

Section: Safety and Regulatory Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Mc Veigh,

Bellan

2024

Lab Chip

View full text Add to dashboard Cite

show abstract

Section: Safety and Regulatory Considerationsmentioning

confidence: 99%

Section: Safety and Regulatory Considerationsmentioning

confidence: 99%

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Mc Veigh,

Bellan

2024

Lab Chip

View full text Add to dashboard Cite

show abstract

“…Moreover, advances in modern automation approaches for the GMP clinical production of 2-[ 18 F]-FDG (1) are discussed elsewhere. [57][58][59][60][61][62] 2.4 Exploring the stereochemical etiology of 2-deoxy-2-…”

Section: Enzymatic Fluorinationmentioning

confidence: 99%

“…As a result, no further studies under hypoxic conditions were conducted. b-2 0 -[ 18 F]-FAZA (60), and b-3 0 -[ 18 F]-FAZL (61) have also been prepared but, to the best of our knowledge, details regarding in vivo or in vitro testing have not been disclosed. 167 In 2002, Patt and co-workers synthesised and evaluated a nitroimadazole FDG derivative, [ 18 F]-FDG-2-NIm (62) to improve on [ 18 F]-FMISO's slow kinetics.…”

Section: F Fmiso -An Alternative Uptake Mechanismmentioning

confidence: 99%

See 1 more Smart Citation

Fluorinated carbohydrates for¹⁸F-positron emission tomography (PET)

2023

View full text Add to dashboard Cite

show abstract

Development of the quantitative PET prostate phantom (Q3P) for improved quality assurance of ¹⁸F‐PSMA PET imaging in metastatic prostate cancer

Fedrigo,

Coope,

Rahmim

et al. 2024

Medical Physics

View full text Add to dashboard Cite

BackgroundPhantoms are commonly used to evaluate and compare the performance of imaging systems given the known ground truth. Positron emission tomography (PET) scanners are routinely validated using the NEMA image quality phantom, in which lesions are modeled using 10 to 37 mm fillable spheres. The NEMA phantom neglects, however, to model focal (3–10‐mm), high‐uptake lesions that are increasingly observed in prostate‐specific membrane antigen (PSMA) PET images. PSMA‐targeting radiopharmaceuticals allow for enhanced detection of metastatic prostate cancers. As such, there is significant need to develop an updated phantom which considers both the quantitative and lesion detectability of this new paradigm in oncological PET imaging.PurposeIn this work, we present the Quantitative PET Prostate Phantom (Q3P); a portable and modular phantom that can be used to improve and harmonize imaging protocols for 18F‐PSMA PET scans.MethodsA one‐piece cylindrical phantom was designed effectively in two halves, which we call modules. Module 1 was designed to mimic lesions in the presence of background, and Module 2 mimicked very high contrast conditions (i.e., very low background) that can be observed in 18F‐PSMA PET scans. Shell‐less radioactive spheres (3–16‐mm) were cast using epoxy resin mixed with sodium‐22 (22Na), a long half‐life positron emitter with positron range similar to 18F. To establish realistic lesion contrast, the 22Na spheres were mounted in a cylindrical chamber that can be filled with an 18F background (module 1). Thirteen exchangeable spherical cavity inserts (3–37‐mm) were machined in two parts and solvent welded together, and filled with 18F (50 kBq/mL) to model lesions with very high contrast (module 2). Five 2.5‐min PET scans were acquired on a 5‐ring GE Discovery MI PET/CT scanner (General Electric, USA). Lesions were segmented using 41% of SUVmax fixed thresholding (41% FT) and recovery coefficients (RCs) were computed from 5 noise realizations.ResultsThe manufactured phantom is portable (5.7 kg) and scan preparation takes less than 40 min. The total 22Na activity is 250 kBq, allowing it to be shipped as an exempt package under International Atomic Energy Agency (IAEA) regulations. Recovery coefficients, computed using PSF modeling and no post‐reconstruction smoothing, were 130.3% (16 mm), 147.1% (10 mm), 87.2% (6 mm), and 7.0% (3 mm) for RCmax, which decreased to 91.1% (16 mm), 90.6% (10 mm), 53.2% (6 mm), and 3.6% (3 mm) for RCmean in the 22Na spheres. Comparatively, 18F sphere recovery was 110.7% (17 mm), 123.6% (10 mm), 106.5% (7 mm), and 23.3% (3 mm) for RCmax, which was reduced to 76.7% (17 mm), 77.7% (10 mm), 66.8% (7 mm), and 13.5% (3 mm), for RCmean.ConclusionsA standardized imaging phantom was developed for lesion quantification assessment in 18F‐PSMA PET images. The phantom is configurable, providing users with the opportunity to modify background activity levels or sphere sizes according to clinical demands. Distributed to the community, the Q3P phantom has the potential to enable better assessment of lesion quantification and harmonization of 18F‐PSMA PET imaging, which may lead to more robust predictive metrics and better outcome prediction in metastatic prostate cancer.

show abstract

Automation of PET Radiopharmaceutical Quality Control

Cited by 5 publications

References 38 publications

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Fluorinated carbohydrates for¹⁸F-positron emission tomography (PET)

Development of the quantitative PET prostate phantom (Q3P) for improved quality assurance of ¹⁸F‐PSMA PET imaging in metastatic prostate cancer

Contact Info

Product

Resources

About

Automation of PET Radiopharmaceutical Quality Control

Cited by 5 publications

References 38 publications

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Microfluidic synthesis of radiotracers: recent developments and commercialization prospects

Fluorinated carbohydrates for18F-positron emission tomography (PET)

Development of the quantitative PET prostate phantom (Q3P) for improved quality assurance of 18F‐PSMA PET imaging in metastatic prostate cancer

Contact Info

Product

Resources

About

Fluorinated carbohydrates for¹⁸F-positron emission tomography (PET)

Development of the quantitative PET prostate phantom (Q3P) for improved quality assurance of ¹⁸F‐PSMA PET imaging in metastatic prostate cancer